304) elating to microplastics and human health effects. |
305) itory, antiangiogenesis, and proapoptotic effects. |
306) ggregations and increase the degenerative effects. |
307) ry, protein aggregation, and anti-oxidant effects. |
308) PH, nor show adverse cardiac or clinical effects. |
309) portant role in their combined neurotoxic effects. |
310) regulation may meaningfully mediate these effects. |
311) for this disorder is without severe side effects. |
312) tudies have not shown consistent positive effects. |
313) oxidation balancing, and immunomodulation effects. |
314) e two treatment groups or large treatment effects. |
315) elopmental windows for these differential effects. |
316) e previously showed had immune modulatory effects. |
317) versus ADHD risk, indicating independent effects. |
318) g symptoms of endometriosis, with no side effects. |
319) iods, evaluation tools, results, and side effects. |
320) e t distribution for the random treatment effects. |
321) -reducing, and possible anti-inflammatory effects. |
322) ues with both beneficial and pathological effects. |
323) n due to method-related concerns and side effects. |
324) tive topics, are at risk of psychological effects. |
325) ve medicine, brain infection, and adverse effects. |
326) h in bioactive compounds with antioxidant effects. |
327) th both protective and counter-protective effects. |
328) bacterial resistance, and control of side effects. |
329) l dilemmas had severe negative subjective effects. |
330) ong-term follow-ups often showed positive effects. |
331) adapt to climate change and mitigate its effects. |
332) ifies the relative and absolute treatment effects. |
333) llular substrate for mediating these tRNS effects. |
334) on of animal survival, without overt side effects. |
335) , avoiding issues of treatment withdrawal effects. |
336) ould contribute to both (1) offline after-effects in the form of a prolonged increas |
|